The year held a number of surprises, including a few negative studies, as well as a big win for Impella in DanGer Shock.

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

With new data from several studies this year, researchers are chipping away at the question of when to revascularize and how.

Mean CV health score, which ranges from 0 (worst) to 100 (best), was 82.6 in early childhood, 84.1 in mid-childhood, 82.0 in ...

As an end-of-year gift, one fellow offers bits of advice he’s gotten that have helped him succeed in interventional ...

One in 20 of the young adult participants had arrhythmias—some occurred many hours later when they were sobering up.

Complication rates, including bleeding, were significantly lower when the radial artery was used over a second femoral ...

PLATO investigators dismiss the paper as nothing new, but some clinicians say that, after 15 years, it’s hard not to have ...

The nod, just months after topline results from SURMOUNT-OSA came out, makes it the first drug approved for this indication.

This small study suggests there’s much still to learn about how best to handle the complexity of repeat procedures.

This month: texts fail to up adherence, unstable AF risks, survival win for SGLT2 therapy in real-world HFrEF patients, and ...

TCTMD's Yael Maxwell, Laura McKeown, Michael O'Riordan, Caitlin Cox, and Todd Neale describe their standout stories.